Ç÷´ç ¶õ¼Â ½ÃÀåÀº ÅëÁõ ¾ø´Â ÃʹÚÇü ¶õ¼ÂÀÇ °³Ã´ µî ¶õ¼Â ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ȯÀÚ ÄèÀû¼º°ú ÄÄÇöóÀ̾𽺰¡ ´ëÆø Çâ»óÇÏ¸ç ½ÃÀåÀÇ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ´Â °ÍÀ¸·Î ÀÎÇØ 5% ÀüÈÄÀÇ ¾ÈÁ¤µÈ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. ¶ÇÇÑ ¼¿ÇÁÄÉ¾î °ü¸® ¾îÇÁ·ÎÄ¡³ª ÀçÅà ±Û·çÄÚ¿À½º ¸ð´ÏÅ͸µ µð¹ÙÀ̽ºÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
À¯Çüº°·Î º¸¸é ½ÃÀåÀº Ǫ½Ã ¹öư ¶õ¼Â, ¾Ð·Â ÀÛµ¿Çü ¶õ¼Â, Ãø¸é ÀÛµ¿Çü ¶õ¼ÂÀ¸·Î ±¸ºÐµË´Ï´Ù. ±× Áß¿¡¼µµ Ǫ½Ã ¹öư ¶õ¼Â Ä«Å×°í¸®´Â ÀÌ ¶õ¼ÂÀÌ Ç÷¾× »ùÇà äÃë ÇÁ·Î¼¼½º¸¦ º¸´Ù °íÅëÀÌ Àû°í, º¸´Ù Æí¸®ÇÑ °ÍÀ¸·Î ÇÏ¸ç ±Û·çÄÚ¿À½º °Ë»ç¿¡ ´ëÇÑ È¯ÀÚÀÇ ÄÄÇöóÀ̾𽺸¦ Çâ»ó½ÃŲ °ÍÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ´õ ³ôÀº CAGRÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ Çª½Ã ¹öư ¶õ¼ÂÀº ±âÁ¸ ·£½Ì µð¹ÙÀ̽º¸¦ »ç¿ëÇÏ´Â °ÍÀÌ ¾î·Á¿î »ç¶÷µéÀ» Æ÷ÇÔÇØ º¸´Ù Æø³ÐÀº »ç¶÷µéÀÌ ±Û·çÄÚ¿À½º °Ë»ç¿¡ ¾×¼¼½ºÇÒ ¼ö ÀÖ°Ô Çϰí ÀÖ½À´Ï´Ù. À̰Ϳ¡ ÀÇÇØ Ç÷´ç ¶õ¼Â ½ÃÀåÀº È®´ëÇϰí ÀÖ½À´Ï´Ù.
Ç÷´ç ¶õ¼Â ½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚ¿¡ ±â¹ÝÇÏ¿© ȯÀÚ¡¤È¨Äɾî¿Í º´¿ø¡¤Áø·á¼Ò·Î ¾çºÐµË´Ï´Ù. º´¿ø¡¤Áø·á¼Ò Ä«Å×°í¸®¿¡¼´Â ¿¹Ãø ±â°£ Áß Ç÷´ç ¶õ¼ÂÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. À̰ÍÀº ÁÖ·Î Ç÷¾×°Ë»ç ŰƮ¸¦ ÇÊ¿ä·Î ÇÏ´Â ´ç´¢º´ ȯÀÚ°¡ ¸¹Àº °Í°ú °¨¿°ÁõÀÇ À¯ÇàÀÌ Áõ°¡Çϰí ÀÖ´Â °Í¿¡ ÀÇÇÕ´Ï´Ù. ¿¹¸¦ µé¸é ±¹Á¦´ç´¢º´¿¬¸Í(IDF)¿¡ µû¸£¸é 2021³â¿¡´Â ¾à 120¸¸ ¸íÀÇ Ã»³â ¹× û¼Ò³âÀÌ 1Çü ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿ø¿¡¼ÀÇ Áø´Ü °Ë»ç´Â º¸´Ù °í°¡À̹ǷΠȨÄɾî Áø´Ü °Ë»ç´Â ½ÃÀå¿¡ ¸¹Àº ¸ÅÃâÀ» °¡Á®¿É´Ï´Ù.
Ç÷´ç ¶õ¼Â ¾÷°èÀÇ ½ÃÀå µµÀÔ¿¡ °üÇÑ ½ÉÃþ ÀÌÇØ¸¦ À§ÇØ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì Áö¿ª), À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´ Áö¿ª), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ±âŸ ¼¼°è ±¹°¡¿¡¼ ¼¼°èÀÇ Á¸Àç¿¡ ±â¹ÝÇÏ¿© ºÐ¼®µË´Ï´Ù. 2021³â ½ÃÀåÀº ºÏ¹Ì°¡ Áö¹èÀûÀ̾ú½À´Ï´Ù. À̰ÍÀº ÁÖ·Î ÁÂ½Ä »ýȰ¹æ½Ä, °Ç°ÇÏÁö ¸øÇÑ ½Ä½À°ü, À¯ÀüÀû ¼ÒÀο¡ ÀÇÇØ ´ç´¢º´À¸·Î Áø´ÜµÇ´Â »ç¶÷ÀÌ ÀÌ Áö¿ª¿¡ »ó´ç¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ ¶§¹®¿¡ ´ç´¢º´ÀÇ Á¤±âÀûÀÎ ¸ð´ÏÅ͸µ°ú °ü¸®¸¦ À§ÇÑ Ç÷´ç ¶õ¼Â¿¡ ´ëÇÑ ¼ö¿ä°¡ ´ëÆø Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀº ÇコÄɾî ÀÎÇÁ¶ó°¡ ¹ß´ÞÇϰí ÀÖÀ¸¸ç, ´ç´¢º´ °ü¸®¿¡ °üÇÑ ÀǽÄÀÌ ³ô°í, ´ç´¢º´ À¯º´·üÀÇ Áõ°¡°¡ ½ÃÀåÀÇ ¼ºÀåÀ» ÀϰüµÇ°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é ±¹Á¦´ç´¢º´¿¬¸Í ´ç´¢º´ ¾ÆÆ²¶ó½º Á¦10ÆÇ¿¡ µû¸£¸é 2021³â¿¡´Â ¹Ì±¹¿¡¼ ¾à 3,220¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, 2045³â¿¡´Â 3,630¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Blood glucose lancets are small, disposable medical devices used to prick the skin and obtain a small drop of blood for glucose testing. The market for blood glucose lancets is experiencing robust growth and is expected to continue expanding in the coming years due to the rising prevalence of diabetes and obesity. For instance, the World Obesity Federation predicts that by 2030, one in five women and one in seven men will have obesity. Also, with sedentary lifestyles, unhealthy eating habits, and an aging population, the number of individuals diagnosed with diabetes has been steadily increasing. This has resulted in a higher demand for lancets used for blood glucose monitoring. Moreover, the growing awareness among patients about the significance of regular blood glucose testing for effective diabetes management has further fueled market growth.
The blood glucose lancets market is expected to grow at a steady rate of around 5% owing to the advancements in lancet technology, including the development of painless and ultra-thin lancets, which have significantly improved patient comfort and compliance, thereby driving market demand. Furthermore, the increasing adoption of self-care management approaches and home-based glucose monitoring devices has contributed to the market's growth.
Based on type, the market is segmented into push button lancet, pressure activated lancet, and side activated lancet. Among them, the push button lancet category is to witness higher CAGR during the forecast period owing to these lancets making the process of obtaining a blood sample less painful and more convenient, which has increased patient compliance with glucose testing. Also, push button lancets have made glucose testing more accessible to a wider range of individuals, including those who may have difficulty using traditional lancing devices. This has expanded the market for blood glucose lancets.
Based on end-user, the blood glucose lancets market has been bifurcated into patients/homecare and hospitals & clinics. The hospitals & clinics category is to witness higher adoption of blood glucose lancets during the forecast period. This is mainly due to the large number of diabetic patients who require blood testing kits and the rising prevalence of infectious diseases. For example, as per the International Diabetes Federation (IDF), around 1.2 million youngsters and youths have type 1 diabetes in 2021. Additionally, homecare diagnostic testing generates more revenue for the market because it is more expensive in the hospital.
For a better understanding of the market adoption of the blood glucose lancets industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market in 2021. This is mainly due to the region having a considerable number of individuals diagnosed with diabetes, primarily due to sedentary lifestyles, unhealthy eating habits, and genetic predisposition. This has resulted in a substantial demand for blood glucose lancets for regular monitoring and management of diabetes. Additionally, the region has a well-developed healthcare infrastructure, a high level of awareness regarding diabetes management, and a growing prevalence of diabetes which will drive the growth of the market consistently. For instance, according to the International Diabetes Federation Diabetes Atlas Tenth edition, in 2021, around 32.2 million people in the United States had diabetes, projected to grow to 36.3 million by 2045.
Some of the major players operating in the market include: LifeScan IP Holdings, LLC; DarioHealth Corp; Beurer GmbH; BD; MEDISANA GMBH; Dexcom, Inc.; Abbott; AgaMatrix; Medtronic; and F. Hoffmann-La Roche Ltd.